Results 31 to 40 of about 2,752 (194)

Long-Term Recurrence-Free Outcome After Doxycycline Pleurodesis With Pulmonary Rehabilitation and Nutritional Support in an Underweight Patient With COPD: A Case Report. [PDF]

Respirol Case Rep
Recurrent secondary spontaneous pneumothorax (SSP) in chronic obstructive pulmonary disease (COPD) is associated with structural lung damage and underweight status. In this case, doxycycline pleurodesis combined with pulmonary rehabilitation and nutritional support was associated with sustained lung re‐expansion and a 22‐month recurrence‐free outcome ...
Notariza KR, Pradono P, Widjanantie SC, Rachmi E, Susanto AD.   +4 more
europepmc   +2 more sources

Once-daily indacaterol 75 µg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect

International Journal of COPD, 2014
Thomas M Siler,1 Craig F LaForce,2 Farid Kianifard,3 James Williams,3 Selwyn Spangenthal4 1Midwest Chest Consultants, St Charles, MO, USA; 2North Carolina Clinical Research, Raleigh, NC, USA; 3Novartis Pharmaceuticals, East Hanover, NJ, USA; 4Charlotte ...
Siler TM, LaForce CF, Kianifard F, Williams J, Spangenthal S   +4 more
doaj   +1 more source

Chronic stimulation desensitizes β2-adrenergic receptor responses in natural killer cells. [PDF]

Eur J Immunol
β2‐adrenergic receptor (β2AR) stimulation of NK cells inhibits inside‐out signaling and LFA‐1 activation, explaining the mobilization of NK cells upon acute stress. Repeated or sustained β2AR stimulation desensitizes β2AR via G‐protein switch. Local administration of long‐acting β2‐agonists does not interfere with systemic NK cell functions in asthma ...
Jürgens M, Claus M, Wingert S, Niemann JA, Picard LK, Hennes E, Haasler I, Hellwig B, Overbeck N, Reinders J, Rahnenführer J, Schedel M, Capellino S, Watzl C.   +13 more
europepmc   +2 more sources

Renal Tubular Epithelial Cell-Derived hsa_circ_0008925 From Urine Is Related to Chronic Renal Fibrosis. [PDF]

J Cell Mol Med
ABSTRACT Renal fibrosis (RF) is a crucial pathological factor in the progression of chronic kidney disease (CKD) to end‐stage renal failure, and accurate and noninvasive assays to monitor the progression of renal fibrosis are needed. Circular RNAs (circRNAs) are noncoding RNAs that can be used as diagnostic biomarkers and therapeutic targets for human ...
Shi Y, Chen Y, Xiao Z, Wang Y, Fu C, Cao Y.   +5 more
europepmc   +2 more sources

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. [PDF]

, 2011
Background Relationships between improvements in lung function and other clinical outcomes in chronic obstructive pulmonary disease (COPD) are not documented extensively.
Pinault, Gregory, Nedelman Jerry, Jones, Paul W, James F Donohue, Jones, PW, Donohue, JF, Steve Pascoe, Pinault Gregory, Pascoe Steve, Donohue James F, Lassen Cheryl, Pinault, G, Pascoe, S, Nedelman, J, Pascoe, Steve, Jerry Nedelman, Paul W Jones, Lassen, Cheryl, Jones Paul W, Cheryl Lassen, Gregory Pinault, Nedelman, Jerry, Donohue, James F, Lassen, C   +23 more
core   +2 more sources

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

BMC Pulmonary Medicine, 2012
Background The objective of this study was to evaluate the comparative efficacy of indacaterol 75 μg once daily (OD), tiotropium 18 μg OD, salmeterol 50 μg twice daily (BID), formoterol 12 μg BID, and placebo for the treatment of chronic obstructive ...
Cope Shannon, Zhang Jie, Williams James, Jansen Jeroen P   +3 more
doaj   +1 more source

Efficacy of indacaterol in the treatment of patients with COPD [PDF]

Primary Care Respiratory Journal, 2011
Effective bronchodilation is an important part of the management of patients with chronic obstructive pulmonary disease (COPD) and can improve breathlessness and ability to undertake physical activities. Indacaterol is a new once-daily, long-acting inhaled bronchodilator for COPD.
Paul W, Jones, Neil, Barnes, Claus, Vogelmeier, David, Lawrence, Benjamin, Kramer   +4 more
openaire   +2 more sources

EFEITO AGUDO DO INDACATEROL EM DESFECHOS CLÍNICOS E FUNCIONAIS NOS PORTADORES DE DOENÇA PULMONAR OBSTRUTIVA CRÔNICA (DPOC): UM ENSAIO CLÍNICO RANDOMIZADO

Revista Pesquisa em Fisioterapia, 2013
Introdução:Os broncodilatadores são fundamentais para o tratamento da doença pulmonar obstrutiva crônica (DPOC). O indacaterol é broncodilatador beta-2-agonista de longa ação recentemente aprovado para utilização na DPOC, que tem como principal ...
Thiago Fróes Batista Ribeiro, Fernanda Warken Rosa, Tiago Albertassi Blunck Resende, Aquiles Assunção Camelier   +3 more
doaj   +1 more source

Revealing Airflow–Particle Dynamics in Dry Powder Inhalers

Small, EarlyView.
An integrated framework combining device and formulation characterization, CFD–DEM simulations, and interpretable machine learning is established. This framework reveals how airflow and particle interactions govern powder dispersion across prevailing dry powder inhalers.
Jiale Chen, Ziyi Fan, Qingliang Yang, Yuanyuan Shao, Dongbing Li, Xiaoyang Wei, Xiang Luo, Kaiqi Shi, Gang Yang, Gensheng Yang, Ying Ma, Yuqing Ye, Jesse Zhu   +12 more
wiley   +1 more source

INFLOW study: a prospective observational study for assessment of indacaterol and other bronchodilators in symptomatic chronic obstructive pulmonary disease patients from Egypt

The Egyptian Journal of Bronchology, 2017
Background The INdacaterol eFfectiveness and utiLizatiOn in COPD: real-World evaluation (INFLOW) study demonstrated significant improvements in health status with decreasing Clinical COPD Questionnaire (CCQ) scores in routine clinical practice with ...
Waleed M. El-Sorougi, Dina Abouelwafa
doaj   +1 more source